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Stereotactic Body Radiotherapy
for Primary Prostate Cancer
Gargi Kothari, MBBS1,2 , Andrew Loblaw, MD3, Alison C. Tree, MD1,
Nicholas J. van As, MD1, Drew Moghanaki, MD, MPH4,
Simon S. Lo, MD5, Piet Ost, MD6, and Shankar Siva, PhD2,7
Abstract
Prostate cancer is the most common non-cutaneous cancer in males. There are a number of options for patients with localized
early stage disease, including active surveillance for low-risk disease, surgery, brachytherapy, and external beam radiotherapy.
Increasingly, external beam radiotherapy, in the form of dose-escalated and moderately hypofractionated regimens, is being
utilized in prostate cancer, with randomized evidence to support their use. Stereotactic body radiotherapy, which is a form of
extreme hypofractionation, delivered with high precision and conformality typically over 1 to 5 fractions, offers a more con-
temporary approach with several advantages including being non-invasive, cost-effective, convenient for patients, and potentially
improving patient access. In fact, one study has estimated that if half of the patients currently eligible for conventional fractionated
radiotherapy in the United States were treated instead with stereotactic body radiotherapy, this would result in a total cost
savings of US$250 million per year. There is also a strong radiobiological rationale to support its use, with prostate cancer
believed to have a low a/b ratio and therefore being preferentially sensitive to larger fraction sizes. To date, there are no
published randomized trials reporting on the comparative efficacy of stereotactic body radiotherapy compared to alternative
treatment modalities, although multiple randomized trials are currently accruing. Yet, early results from the randomized phase III
study of HYPOfractionated RadioTherapy of intermediate risk localized Prostate Cancer (HYPO-RT-PC) trial, as well as multiple
single-arm phase I/II trials, indicate low rates of late adverse effects with this approach. In patients with low- to intermediate-risk
disease, excellent biochemical relapse-free survival outcomes have been reported, albeit with relatively short median follow-up
times. These promising early results, coupled with the enormous potential cost savings and implications for resource availability,
suggest that stereotactic body radiotherapy will take center stage in the treatment of prostate cancer in the years to come.
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Introduction
As of 2016, more than 3.3 million men are living with prostate
cancer in the United States1 with more than 180 000 new cases
diagnosed each year, of whom 92% present with localized
disease. Conventional curative treatment options for localized
disease include radical prostatectomy, external beam radiother-
apy (EBRT), and brachytherapy. Stereotactic body radiother-
apy (SBRT) is an emerging treatment option which allows for
extreme hypofractionation using modern technologies. This
review will outline the efficacy and toxicity outcomes of SBRT
and highlight specific issues and controversies surrounding
patient selection, treatment planning and delivery, use of
androgen deprivation therapy (ADT), and follow-up. The
review will conclude by highlighting currently accruing studies
and areas for future research.
Rationale for High Dose per Fraction
Radiotherapy
Extreme hypofractionation using SBRT for prostate cancer
may have radiobiological advantages compared to convention-
ally fractionated external beam radiotherapy (CFRT). The rel-
atively low a/b ratio of prostate cancer, estimated to be
between 1 and 2 Gy, may confer sensitivity to high dose per
fraction.2-5 In addition, the a/b ratio of prostate cancer may be
lower than surrounding organs at risk (OARs), including the
rectum and bladder, thereby allowing hypofractionation to
improve the therapeutic ratio and deliver similar rates of effi-
cacy with the same or lower rates of complication than con-
ventional fractionation.3,5 Randomized evidence suggests that
dose-escalated CFRT is associated with improvement in bio-
chemical and disease-specific outcomes.6-11 Furthermore,
medium-term results from recent randomized studies have
shown moderately hypofractionated regimens of 2.5 to 3 Gy
to be noninferior to CFRT with respect to biochemical control
without a detriment to toxicity and have led to the adoption of
moderately hypofractionated radiotherapy at treatment centers
worldwide.12-14 It is important to note, however, that neither
use of dose escalation nor hypofractionation has a demon-
strated overall survival advantage, and therefore, management
of associated toxicities with these approaches is critical.
It is believed that SBRT-induced tumor cell kill may also be
mediated through different pathways compared to CFRT. The
tumor microenvironment, and specifically the tumor vascula-
ture, may be a significant factor in the effectiveness of SBRT.
The endothelial acid sphingomyelinase pathway generates
proapoptotic second messenger ceramide, which induces apop-
tosis of endothelial cells, microvascular dysfunction, and sec-
ondary tumor cell death.15 This pathway appears to be
generated in a dose-dependent manner, particularly with doses
greater than 8 Gy per fraction.16 The role of ceramide is further
supported by clinical studies which showed elevation in serum
ceramide levels following SBRT is correlated with tumor
response, suggesting both its mechanistic role in cell kill and
its potential future role as a biomarker.17,18
In addition to radiobiological considerations, SBRT has
practical advantages over surgery, CFRT, and brachytherapy,
including being noninvasive, time efficient, and cost-effective,
potentially resulting in improved access and greater patient
satisfaction.19,20 Although cost arguments in one country may
not readily translate to others, there are a number of studies
from different countries that aim to quantify the cost benefit of
SBRT. A Canadian cost–utility study compared SBRT to low
dose rate (LDR) brachytherapy and CFRT for a 66-year-old
with low-risk prostate cancer followed annually.21 The study
found that SBRT and LDR were more cost-effective, with
SBRT being Can$5266 less expensive and delivering 0.53
higher quality-adjusted life years compared to CFRT. A similar
American study also showed cost savings with SBRT com-
pared to CFRT, with a calculated savings of US$13 279 per
patient.20 The same study estimated that if half of the patients
currently eligible for CFRT were to be treated instead with
SBRT, this would result in a total cost savings of US$250
million per year. The impact of radiotherapy planning and
delivery techniques was further investigated in a study that
found arc-based SBRT (Can$4368) to be the least expensive
and fixed gantry-based CFRT the most expensive (Can$7992)
of EBRT techniques to treat prostate cancer.22 Meanwhile,
CFRT with protons has been shown to be over 2.5 times more
expensive than SBRT assuming equal effectiveness of thera-
pies.23 Cost savings with SBRT compared to CFRT are also
realized at a patient level, with an average of Can$5517 saved
per patient for costs related to time off work, transport, and
parking.24 Cost and time saved for patients are an important
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consideration, with length of CFRT treatment being cited as
one of the most frequent dislikes among patients receiving
prostate cancer treatment.25
Clinical Outcomes—Efficacy, Toxicity, and
Quality of Life
There are multiple published prospective single-arm series
investigating the use of SBRT (see Table 1). The largest is a
multi-institutional report on 1100 patients (641 low, 334 inter-
mediate, and 125 high risk) with clinically localized prostate
cancer enrolled in separate phase II trials from 8 institutions
between 2003 and 2011.26 Patients were treated using Cyber-
Knife (Accuray, Sunnyvale, California) to a dose of 35 to 40
Gy in 4 to 5 fractions, with dose normalized to the 90% isodose
line, such that the prescription dose covered at least 95% of the
planning target volume (PTV). With a median follow-up of 36
months, the 5-year biochemical relapse-free survival (bRFS)
defined as nadir þ 2 ng/mL was 95%, 84%, and 81% for low-,
intermediate-, and high-risk prostate cancer, respectively. No
correlation was shown with the total dose delivered or use of
ADT. Updated results of this series were presented recently in
abstract form for 1644 patients (892 low and 752 intermediate
risk), with a median follow-up of 7.2 years.27 The 5-year and
10-year bRFS rates were 98% and 94% in the low-risk and 96%
and 90% in the intermediate-risk group, respectively. The
severe acute toxicity rate was only 0.2% (5 patients with grade
3 genitourinary [GU] toxicity). Thirty (2%) patients experi-
enced a late grade 3 GU toxicity (including urinary strictures,
hematuria, and retention) and 1 patient a late grade 4 GU toxi-
city (hemorrhagic urethritis). One patient had a late grade 4
gastrointestinal (GI) toxicity (fistula-in-ano). A subset of these
patients (n¼ 864) also had complete quality of life (QOL) data
collected.28 Using the Expanded Prostate Cancer Index Com-
posite (EPIC),29 the authors reported mean baseline urinary,
bowel, and sexual domain scores of 89, 95, and 53, which
worsened to 81, 83, and 48 at 3 months posttreatment. Patients
subsequently showed recovery at 6 months in the urinary and
bowel domains, with recovery to baseline scores of 91 and 96,
respectively, at 5 years. However, sexual function continually
declined posttreatment.
The largest single-institution series published by Katz et al
is from Flushing, New York, with patients from this series also
included in the above pooled analysis.30 There were a total of
324 low-, 153 intermediate-, and 38 high-risk patients included
with the 8-year bRFS being 94%, 84%, and 65%, respectively.
An updated 10-year analysis of 230 low-risk patients showed
93% bRFS.31 There was no difference in efficacy seen between
35 and 36.25 Gy. Toxicity was retrospectively reported in a
cohort of 477 low- and intermediate-risk patients, with 1.7% of
patients experiencing Radiation Therapy Oncology Group late
grade 3 to 4 GU toxicity, comprising of retention requiring
surgery and bleeding requiring laser coagulation.32 Both these
patients received 36.25 Gy. No severe late GI toxicities were
seen; however, this may have been underreported, given it was
collected retrospectively. Outcomes appear to be broadly
similar across CyberKnife series, including results presented
by Meier et al of the largest multi-institutional series33 and by
Tree et al of the first United Kingdom series, which found 2
patients with grade 3 toxicity during radiotherapy, however
none following treatment, suggesting that acute toxicities may
peak earlier than that captured on studies recording toxicity
first at 1 month post-SBRT.34
Outcomes are similar between CyberKnife and gantry-based
platforms. The largest gantry-based series comprised of low-
risk patients with cancer treated to 35 Gy in 5 fractions deliv-
ered to the clinical target volume (CTV; with 99% of CTV
receiving the prescription dose), with an excellent 5-year bRFS
of 98% and with 1% rate of late severe GU (temporary cathe-
terization in patient with 300 cm3 bladder diverticulum) and GI
toxicity (anal fistula in patient with background
diverticulitis).35
The efficacy and toxicity outcomes in the above larger stud-
ies are similar to results published by smaller series. In general,
the results show excellent 5-year bRFS rates of 95% or greater
for low-risk disease. The reported toxicities are also low, with
late grade 3 GU and GI toxicities usually less than 2%. The
main exception to this was seen in a dose escalation study of up
to 50 Gy in 5 fractions (see Table 2 for biological equivalent
dose calculations), which reported a 7% and 6% rate of Com-
mon Terminology Criteria for Adverse Events (CTCAE) v.3.0
late  grade 3 GI and GU toxicity, respectively, including
grade 4 cystitis requiring ureteroileal diversion, grade 4 rectal
bleeding requiring intensive care admission, and 6 patients who
required a colostomy.36 Analysis of rectal dosimetry revealed
that patients on this study were significantly more likely to
develop late rectal toxicity if the rectal wall received V50 Gy
>3 cm3, >35% of the rectal wall circumference received 39 Gy,
and >50% of the rectal wall circumference received 24 Gy.
Quality of life data also appear consistent across the literature
with initial deterioration over the first few months in urinary
and bowel domains, followed by subsequent recovery to base-
line over the next 6 to 12 months.37,38 Sexual function, how-
ever, usually declined post-SBRT without recovery.28,38
Which Patients Benefit From SBRT?
As yet, there is only one randomized study comparing SBRT to
an alternative treatment modality, the Phase III study of
HYPOfractionated RadioTherapy of intermediate risk loca-
lized Prostate Cancer (HYPO-RT-PC) trial (see Table 1).39
This trial compared CFRT (78 Gy in 39 fractions) to extreme
hypofractionation (42.7 Gy in 7 fractions, with an equivalent
dose in 2 Gy per fraction [EQD2] of 78 Gy for a/b¼ 3) in 1200
intermediate-risk patients. Radiotherapy was delivered to the
prostate alone. A 7-mm CTV to PTV margin was used. Image
guidance with fiducial markers was employed. Median follow-
up time was 4.2 years. Acute grade 2 GI toxicity was slightly
higher in the SBRT arm (9.4% vs 5.3%, P ¼ .023); however,
GU toxicity was similar (27.6% vs 22.8%, P¼ .11). At 2 years,
there was no difference in physician reported grade 2 GI (2.2
vs 3.7%, P ¼ .20), or GU (5.4% vs 4.6%, P ¼ .59) toxicity, or
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rates of impotence (34% in both arms). Patient-reported out-
come measurement (PROM) data revealed significantly worse
acute bowel toxicity in 7 of 10 items in the SBRT arm; how-
ever, the difference disappeared at 3 months. Urinary function
PROM scores at 1 year were worse in 4 of 10 items in the
SBRT arm. Efficacy results are awaited as the data mature.
Another study compared QOL outcomes between 2 sequen-
tial phase II studies, with the first study utilizing SBRT to 35
Gy in 5 fractions over 5 weeks and the second 15 Gy high dose
rate (HDR) brachytherapy followed by EBRT to 37.5 Gy in 15
fractions.49 This study revealed significant differences between
the 2 studies in EPIC urinary (P < .0001), bowel (P ¼ .0216),
and sexual (P ¼ .0419) domain scores, favoring SBRT.
In lieu of randomized efficacy evidence, some centers have
compared SBRT to alternative radiotherapy techniques using
propensity score-matched analyses, including a Canadian study
of 602 low-risk patients, which showed superior bRFS with
SBRT compared to CFRT, while bRFS was similar between
SBRT and LDR brachytherapy.50 An American study similarly
found, on a propensity score-matched analysis of 263 patients
with nonmetastatic prostate cancer, no difference in 5-year
freedom from biochemical failure (FFBF) or toxicity between
SBRT and CFRT (90% vs 90%, P ¼ .644).51 A retrospective
multi-institutional analysis that compared the outcomes of
patients who received either SBRT or HDR brachytherapy
as monotherapy for 437 intermediate-risk patients found a
bRFS of 96.3% with no significant difference according to
treatment type.52 Overall, survival for SBRT also appears
comparable to other treatment modalities, with an analysis
of 5430 patients with localized prostate cancer on the US
National Cancer Database revealing no difference in overall
survival between patients treated with SBRT or CFRT.53
Another study looking at the comparative effectiveness of
various prostate cancer treatment using previously published
data suggested that while both HDR and SBRT showed pro-
mising results, the available data for these modalities were not
as robust as for CFRT as yet.54
Overall, the above results suggest that SBRT may be an
equally effective and safe treatment option compared to alter-
native radiotherapy modalities for patients with low- and
intermediate-risk prostate cancer. We eagerly anticipate results
from forthcoming randomized studies, which will allow us not
only to better select between radiotherapy options but also to
better counsel our patients between radiotherapy and surgery.
Finding the Right Dose
While a spectrum of total doses and fraction sizes are reported
in the SBRT literature, most common doses in the order of 35
to 36.25 Gy in 5 fractions delivered to the PTV are employed
based upon the isolate-effects principle, which results in an
EQD2 of 70 Gy for late effects (a/b ¼ 3 Gy) and 85 Gy for
tumor effects (a/b ¼ 1.5 Gy; see Table 2). Yet, there are no
published randomized studies assessing the efficacy of SBRT
dose escalation. The majority of prospective studies comparing
dose regimens are limited by confounding factors including
differences in patient population, inconsistent use of ADT, and
relatively short follow-up periods, with variable results for
efficacy. One report comparing doses used in 2 prospective
Canadian trials employing 35 Gy (Prostate Hypofractionated
Accelerated RadioTherapy [pHART] 3) and 40 Gy (pHART6)
in 5 fractions found no significant difference in 4-year bRFS
(98.7% vs 100% respectively, P ¼ .19).44 Interestingly, 40 Gy
was significantly associated with a lower median prostate-
specific antigen (PSA) at 3 years on multivariate analysis, sug-
gesting that potentially with longer follow up, a difference in a
bRFS may be seen.55 Supporting this finding is a phase I dose
escalation study presented at the 2017 American Society for
Radiation Oncology (ASTRO) annual meeting of 136 patients
comparing 4 dose levels of 32.5, 35, 37, and 40 Gy in 5 frac-
tions.41 This study showed improved 3-year bRFS with higher
doses (83%, 85%, 90%, and 98% respectively, P < .001) and
lower rates of positive posttreatment biopsies (45%, 12%, 17%,
5% respectively, P < .001), with low rates of severe late toxi-
city (no  grade 3 rectal and 1 late grade 3 urinary toxicity).
Further dose escalation of 50 Gy in 5 fractions was studied
within a multi-institutional phase I/II trial of 91 low- and
intermediate-risk patients treated with SBRT to 45 Gy (n ¼
15), 47.5 Gy (n ¼ 15), and 50 Gy (n ¼ 61).36 There was only 1
biochemical failure at 5-year follow-up of a patient treated to
45 Gy in this study; however, the late toxicity rates were unac-
ceptably high as previously discussed.56
Most recently, a randomized phase II study of 30 patients,
published in abstract form only, reported on the use of single-
fraction radiotherapy in prostate cancer, comparing 24 Gy in a
single fraction to 45 Gy in 5 daily fractions.57 The end points
reported were 3-month acute treatment-related toxicity and
patient-reported QOL. The early results were promising with
no acute grade 2 toxicity, although there were higher grade 1
Table 2. Doses for Prostate Stereotactic Body Radiotherapy.
a/b Ratio
35 Gy in 5 Fractions 36.25 Gy in 5 Fractions 40 Gy in 5 Fractions 50 Gy in 5 Fractions
BED EQD2 BED EQD2 BED EQD2 BED EQD2
1 280 93 299 100 360 120 550 183
1.5 198 85 211 91 253 109 383 164
2 158 79 168 84 200 100 300 150
3 117 70 124 74 147 88 217 130
10 60 50 63 52 72 60 100 83
Abbreviations: BED, biological equivalent dose; EQD2, equivalent dose in 2 Gy per fraction.
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GU and GI toxicities in the single fraction compared to the 5
fraction arm (GU 41% vs 18% and GI 8% vs 0%). Quality of
life results revealed no difference in mean EPIC scores
between the 2 arms, with both arms finding a decrease in 1-
month urinary scores to 6% and 8%, which recovered to base-
line at 3 months, with a similar trend seen in International
Prostate Symptom Score (IPSS). Importantly, this study uti-
lized volumetric-modulated arc therapy and image-guided
radiotherapy techniques, with urethral sparing, real-time
motion management, a Foley catheter loaded with beacon
transponders, and insertion of an endorectal balloon filled with
150 cc air to induce temporary ischemia of the anterior rectal
tissues. Although this study provides an intriguing look into a
future when SBRT can be delivered in a single fraction, small
patient numbers and short follow-up limit interpretation of this
study, with greater patient numbers and longer-term data
needed to better assess its efficacy and potential risks of late
toxicity. Another single-arm phase I/II trial (NCT03294889)
assessing single-fraction SBRT to 19 Gy to the prostate with
or without the proximal seminal vesicles is currently accruing
and aiming to recruit 45 participants to assess toxicity and 3-
year bRFS.
An alternative option to escalate the dose delivered to the
prostate is to combine CFRT with a SBRT boost. One study
from Georgetown University included 59 high-, 45
intermediate-, and 4 low-risk patients treated with SBRT to
19.5 Gy in 3 fractions followed by EBRT to the prostate, prox-
imal seminal vesicles, and areas of extra-prostatic extension
using a 1-cm CTV to PTV margin to a dose of 45 to 50 Gy
in 25 to 28 fractions.58 The 3-year FFBF in this study appeared
promising, being 100% for intermediate and 90% for high-risk
patients, although noting that 64% of patients received ADT
prior to RT. There was a statistically significant deterioration in
EPIC GU and GI QOL scores at 1 month, which subsequently
improved, although not to baseline, at 24 months, with 13.7%
and 5% of men reporting their urinary or bowel function,
respectively, to be a “moderate to big problem” at this point.
In addition to total dose and dose per fraction, there is con-
siderable variation applied to the scheduling of treatment
within studies. Although no studies to our knowledge have
reported improvement in SBRT efficacy with variation in over-
all treatment time, a prospective study of 67 patients with a
median follow-up of 2.7 years suggested that alternate day
compared to consecutive day treatment resulted in favorable
late grade 1 to 2 GI (5% vs 44%, P ¼ .001) and GU (17% vs
56%, P ¼ .007) toxicities.59 There was no difference in higher
grade toxicities seen. This is supported by the results of the
Prostate Accurately Targeted Radiotherapy Investigation of
Overall Treatment Time study, which is a Canadian phase II
trial with results in press, randomizing 152 patients to 40 Gy in
5 fractions delivered either weekly or on alternate days.40,60
With a median follow-up of 47 months, this study showed
improved acute urinary (78% vs 94%, P ¼ .006) and bowel
(68% vs 90%, P ¼ .002) QOL (as defined by the proportion of
patients who had a >0.5 standard deviation decline in EPIC
scores) in patients undergoing weekly compared to alternate
day treatment. There was no significant difference in late urin-
ary or bowel toxicity at 2 years. A similar ongoing study in
Europe has randomized 170 patients to alternate day versus
weekly SBRT to 36.25 Gy in 5 fractions (NCT01764646), and
results are awaited.
Treatment Volume—Prostate, Pelvis, and/or
Dominant Nodule
Amajority of the studies assessing the role of SBRT in prostate
cancer have limited the radiotherapy volume to the prostate
alone, without treating the pelvis (see Figure 1). Some studies,
however, have used SBRT as a boost to CFRT. This is modeled
on studies using brachytherapy as a form of dose escalation, the
use of which was supported by the randomized Androgen Sup-
pression Combined with Elective Nodal and Dose Escalated
Radiation Therapy trial which combined EBRT with bra-
chytherapy and showed a halving of biochemical failure com-
pared to EBRT alone to a dose of 78 Gy.61 Most of the SBRT
boost series are retrospective and have assessed predominantly
intermediate- and high-risk patients and show FFBF rates of
between 77% and 100% with low rates of severe toxicities.62-66
Meanwhile, a comparison of high-risk patients treated
within a prospective study with SBRT monotherapy (35-
36.25 Gy in 5 fractions) or CFRT (45 Gy in 25 fractions
to prostate and nodes) followed by SBRT boost (18-21 Gy
in 3 fractions) did not show an improvement in bRFS with
the addition of pelvic EBRT (P ¼ .86) and found worse late
rectal toxicity (grade 2 GI toxicity 0% vs 13%, respectively,
P ¼ .002).63
Another approach to treatment of the pelvis is with SBRT,
with a boost to the prostate (see Figure 2). Two studies that
assessed this approach were the SABR Including Regional
Lymph Node Irradiation for Patients With High Risk Prostate
Cancer (SATURN) and Fairly brief Androgen suppression and
StereoTactic Radiotherapy for high risk prostate cancer
Figure 1. CyberKnife plan to 36.25 Gy in 5 fractions.
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(FASTR) studies.67-69 In both studies, patients received 25 Gy
in 5 weekly fractions, with a hypofractionated simultaneous
integrated boost (SIB) to the prostate and seminal vesicles to
40 Gy. Combined early toxicity results from the studies
revealed, in particular, a high rate of rectal toxicity, with 12
out of 45 patients experiencing rectal bleeding. Rectal bleeding
was more frequent and of higher grade in patients in the
FASTR (8/15 including 5 patients with grade 2 toxicities) com-
pared to the SATURN trial (4 of 30, all grade 1 toxicities). This
was thought to be due to inclusion of seminal vesicles in the
CTV and larger 5 mm PTV expansions in the FASTR study, as
well as differences in PTV planning (FASTR used D95 40
Gy, whereas SATURN used D95 33.25 Gy) and rectal con-
straints (FASTR used D50 29 Gy whereas SATURN used
D50 20 Gy). In particular, the V20 Gy was significantly
higher in patients with  grade 2 bleeding (68% vs 40%, P <
.001) and V40 Gy was significantly higher in patients with any
grade bleeding (1.53% vs 0.69%, P ¼ .006).
A phase I/II study has also assessed the use of SBRT to the
pelvis to 25 Gy in 5 weekly fractions, following the initial use
of HDR brachytherapy to 15 Gy in a single fraction to the
prostate, with up to 22.5 Gy to a magnetic resonance imaging
(MRI) identified nodule.70 Early results with a median follow-
up of 13.8 months revealed 45% acute CTCAE v3.0 grade 2
GU and 10% grade 2 GI toxicities. There were also 3 acute
grade 3 toxicities, all necessitating urinary catheterization in
the immediate post-HDR period, and no grade 3 late toxicities.
Mature data for this study are still pending.
Identification and treatment of an MRI-detected dominant
intraprostatic lesion using brachytherapy or other focal modal-
ities has been extensively reported71 and is now also being
studied using SBRT. One study reported in abstract form
treated 10 low- to intermediate-risk patients to 40 Gy in 5 frac-
tions to the whole prostate with an SIB to MRI detected lesions
to 42.5 to 45 Gy in 5 fractions, while treating another 6 patients
who were unable to have MRI to 37.5 Gy in 5 fractions without
a SIB.72 Early results with a median follow-up of 8 months
showed no grade 3 or 4 acute or late toxicities and a small
deterioration in IPSS from 8.2 to 10.4 at 6 weeks (P ¼ .02).
The trial continues to collect follow-up data on toxicity and
tumor control, and we await long-term results to assess whether
this may be a safe and effective method of dose escalation.
Technical Considerations—Treatment
Planning and Delivery
Target delineation is critical to the use of SBRT. The CTV
typically incorporates the prostate, with or without the proxi-
mal seminal vesicles and areas of extracapsular extension.
Increasingly, image fusion of MRI sequences is being incorpo-
rated into practice.73 Previous studies have shown significant
variation exists in prostate contouring, emphasizing the need
for adequate quality assurance.74,75 Incorporation of MRI
images reduces interobserver variation in target delineation
compared to computed tomography images alone.76 Contour-
ing guidelines, such as the recently published European Society
for Radiotherapy and Oncology guidelines, aims to standardize
the definitions for target volumes and OAR and may also help
to improve consistency.77 Planning target volume expansions
are typically 3 to 5 mm, with tighter constraints posteriorly to
Table 3. PACE Dose Constraints.78
Organ At Risk Dose Constraint
Rectum V18.1 Gy <50% (ie, 50% rectum <18.1 Gy)
V29 Gy <20% (ie, less than 20% rectum
receiving 29 Gy)
V36 Gy <1 cc
Bladder V18.1 Gy <40%
V37 Gy <10 cc (optimal V37 Gy <5 cc)
Prostatic urethra (if
visualized)
V42 Gy <50% (optimal, not mandatory)
Femoral head V14.5 Gy <5%
Penile bulb V29.5 Gy <50%
Testicular Blocking structure
Bowel V18.1 Gy <5 cc
V30 Gy <1 cc
Abbreviations: PACE, prostate advanced in comparative evidence; V, volume.
Figure 2. Stereotactic body radiotherapy to the pelvis.
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spare the rectum. The dose is often prescribed to the 90%
isodose (may range between 75% and 90%), with the aim of
the prescription dose covering at least 95% of the PTV,
although other centers aim for the prescription dose to cover
at least 99% of the CTV. An example of OAR dose constraints
being used for the currently accruing international Prostate
Advanced in Comparative Evidence (PACE) trial is given in
Table 3.78 In particular, maintaining a rectal D1 cc <35 Gy and
penile bulb V35 Gy <4% (using 5 fraction regimen) has been
shown to be critical and independently predictive of decline in
bowel QOL scores.79
The majority of the literature published to date has incorpo-
rated the use of CyberKnife to deliver SBRT, although more
recent series have used gantry-based linacs with similar out-
comes.35,80 The main technical challenge in delivery of SBRT
to the prostate is management of inter- and intrafraction motion
of the prostate gland, which can depend on continuous rectal
and bladder filling, even while the beam is on. Image guidance
systems are key to allowing safe delivery of SBRT, with real-
time motion tracking systems incorporating the use of 3 to 4
fiducial markers commonly employed. More recently, the
introduction of real-time MRI images during treatment deliv-
ery allows for continuous intrafractional tracking of the target
and may result in improved toxicity profiles and allow for even
further dose escalation.81 Another method currently under
investigation is the use of kilovoltage intrafraction monitoring
(KIM), which also offers a real-time automated image gui-
dance system by using periodic X-rays of fiducial markers
while the beam is on to facilitate corrections with alignment,
or even tracking with multileaf collimators during treatment.82
There are additional strategies to control for bowel and bladder
size including prescription of a strict diet, bowel regimen, and/
or laxatives,38,45,83,84 bladder catheterization,45 or bladder
emptying followed by a specified consistent intake of water.35
The rectum is of particular concern as not only an organ that
contributes to target motion but also as a critical OAR. Some
institutions have used endorectal balloons to immobilize the
prostate,84 whereas others have employed SpaceOAR hydrogel
spacers to push the rectum away from the prostate (Augmenix
Inc, Waltham, Massachusetts).85
Use of ADT
For many years, ADT has been commonly used in addition to
radiotherapy.86 Although the addition of ADT to CFRT has
been shown to improve overall survival in intermediate- and
high-risk patients,87-89 there are limited data in the dose esca-
lated and SBRT setting. In the pooled analysis of 1100 patients,
there was no predefined criteria on the use of ADT, with only
147 patients undergoing endocrine therapy and no difference in
5-year FFBF (93%with ADT vs 91%without ADT, P¼ .71).26
The relatively poorer efficacy of SBRT for high-risk patients,
however, may prove to be an area in which additional treatment
modalities such as ADT may play a role. Further research in
this area is required.
Follow-Up
Prostate-specific antigen kinetics following SBRT tend to show
lower PSA nadirs (nPSA) compared to CFRT, but comparable
or slightly higher than brachytherapy,50,90 with nPSA levels
typically approximating 0.2 ng/mL with a trend for lower nPSA
levels with higher biological doses.26 The nPSA tends to be
lower and PSA slopes larger following SBRT compared to
CFRT, with the difference becoming evident particularly 2 to
3 years following treatment, with the PSA continuing to fall
with SBRT and plateauing for CFRT.90,91 Time to nPSA, there-
fore, is usually longer with SBRT, with 1 series showing a
median time to nPSA of 7.8 and 5.9 years for doses of 35 and
40 Gy in 5 fractions, respectively.42,43 Compared to bra-
chytherapy, however, SBRT produces similar or higher nPSA
levels.50,90 Benign PSA bounce is also a phenomenon which is
reported at varying rates within the literature between 16% and
44%, with a median bounce height of approximately 0.5 ng/
mL, and at a median time between 15 and 36 months,26,44,90
which urges caution whenever using early PSA as a surrogate
for efficacy. Most SBRT trials continue to use the Phoenix
definition of biochemical failure (nadir þ 2 ng/mL), even
though this definition was originally developed as an early end
point for patients undergoing conventionally fractionated
radiotherapy. There are insufficient data as yet to suggest
whether this definition is the most appropriate for patients
undergoing SBRT or whether an alternative definition should
be used. The PACE trial also incorporates the use of the orig-
inal ASTRO definition of biochemical failure (3 consecutive
PSA rises) within the first 24 months, with the aim of avoiding
benign PSA bounces post-SBRT being classified as biochem-
ical failure.
Stereotactic Body Radiotherapy for
Local Recurrence
With the advent of improved imaging techniques such as
prostate-specific membrane antigen positron emission tomo-
graphy, isolated prostate-only failures are becoming increas-
ingly recognized. There are a number of small series, albeit
with limited follow-up and highly selected patient populations,
which have explored the use of SBRT in the setting of local
failure. A systematic review of patients receiving pelvic reirra-
diation with SBRT published in 2017 found 4 studies of pros-
tate cancer with 82 patients.92 Most of the patients on these
studies had intraprostatic or prostate bed recurrence and
received ADT. The largest prospective series reported on 29
patients with biopsy-proven locally recurrent prostate cancer
treated with SBRT reirradiation without ADT to the whole
prostate to 34 Gy in 5 fractions.93 Median follow-up was 24
months, and, in this time, there were no local failures, with a 2-
year bRFS of 82%. Toxicity was acceptable with 7% of
patients, experiencing  grade 3 GU toxicity and no severe
GI toxicity. The largest retrospective series recently published
in 2018 included 50 patients who received SBRT reirradiation
to 30 Gy in 5 fractions.94 Eleven patients were on ADT at the
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time of SBRT. With a median follow-up of 21 months, 27
(54%) patients had no evidence of disease, 3 (6%) patients
pursued ADT with stable PSA levels, and 20 (40%) patients
experienced biochemical relapse. Only 1 patient had a severe
late toxicity, being grade 3 hematuria. Another recent retro-
spective study analyzed 18 patients who underwent focal reir-
radiation with SBRT for intraprostatic recurrence to 35 Gy in 5
fractions.95 With a short median follow-up of 14.5 months, 10
patients had biochemical no evidence of disease, 5 patients had
biochemical recurrence after an initial response, and 3 patients
did not respond to SBRT. Treatment was reasonably well tol-
erated, with 1 late grade 4 GU toxicity and no late grade 3 or 4
GI toxicities. Although these series have a number of limita-
tions, the results are promising and suggest that SBRT may
offer a comparable if not favorable alternative to salvage treat-
ment options such as surgery, although further prospective
research with larger numbers in this area is needed.
Future Directions
Numerous randomized studies are ongoing that will soon shed
light on the comparative efficacy and toxicity of SBRT. These
include the Scandinavian HYPO-RT-PC trial comparing SBRT
to CFRT, for which early toxicity results are available, and the
United Kingdom-led international PACE trial, which includes
patients from the United Kingdom, Canada, and Ireland and
compares SBRT to surgery (PACE-A) or CFRT/moderately
hypofractionated RT (PACE-B) (NCT01584258). The PACE-
B has now fully recruited 872 patients with data maturing. The
role of SBRT in high-risk patients, however, is still to be
elucidated, as well as the role of adjuvant systemic options
such as ADT.
Emerging technologies, including the use of KIM and real-
time MRI image guidance systems, will likely translate into
even lower rates of toxicities. These technologies may also
facilitate the safe escalation of even higher daily fractions and
potentially the reduction in the number of fractions, including
the use of single-fraction radiotherapy in the future. Magnetic
resonance image guidance may also enable incorporation of
daily adaptive radiotherapy planning, allowing for accommo-
dation of any changes to the prostate or rectal anatomy, without
adversely affecting the dosimetry to either the target or OARs.
Conclusion
Multiple prospective studies with medium-term follow-up sup-
port the use of SBRT in low- and intermediate-risk localized
prostate cancer, with reported high rates of biochemical control
and low rates of late toxicity. Additionally, SBRT has practical
and economic advantages to alternative modalities, with the
potential for large cost reductions at a governmental and patient
level, and improved radiotherapy access and waiting times for
patients (see Table 4 for advantages and disadvantages of
SBRT). Forthcoming randomized trials will allow us to better
compare SBRT outcomes with alternative treatment modalities,
as well as optimize radiotherapy dose, schedule, and volumes.
Further research into the role of SBRT and ADT in high-risk
patients, as well as incorporation of emerging technologies, will
allow us to continue to improve outcomes for our patients.
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